Slide 1: Aroa Biosurgery March Quarterly (Q4 FY24) Report
For personal use only AROA BIOSURGERY (ARX) MARCH QUARTERLY (Q4 FY24) REPORT Unlocking regenerative healing for everybody
Slide 2: Important Notice and Disclaimer
|2 Important Notice and Disclaimer This presentation (Presentation) is dated 30 April 2024 and has been prepared by Aroa Biosurgery Ltd, New Zealand company number 1980577, ARBN 638 867 473 (AROA or the Company). Information in this Presentation The information in this Presentation is of a general b
Slide 3: AROA at a Glance
|3 AROA at a Glance Well established high-growth soft tissue regeneration company For personal use only Four product AROA ECM platform families for new products, line >US$3B1 TAM predominantly sold to US extensions & enables AROA’s hospitals for existing products tissue apposition platform US Direct
Slide 4: AROA ECM – Structure & Biology for Regenerative Healing
|4 AROA ECM – Structure & Biology for Regenerative Healing Unique Extracellular Matrix (ECM) derived from ovine forestomach with proven tissue regeneration properties across multiple products1-6 For personal use only 1. Irvine, S. M., et al. (2011). "Quantification of in vitro and in vivo angiogenes
Slide 5: Q4 Financial highlights
|5 Q4 Financial highlights Strong cash receipts from customers of NZ$18.0 million, reflecting a continuation of the prior quarter’s step-up in Myriad and OviTex /OviTex PRS sales. For personal use only Positive net cash inflows from operations of NZ$0.3 million, exceeding Q4 breakeven expectations.
Slide 6: AROA Sales
|6 AROA Sales Continuing expansion in Myriad sales access during the quarter, with Myriad active accounts increasing from 205 to 218 during the quarter. For personal use only
Slide 7: TELA Bio Sales
|7 TELA Bio Sales Strong CY23 OviTex PRS and OviTex sales, with TELA Bio, Inc. (‘TELA Bio’) reporting CY23 revenue of US$58.5 million (41% pcp growth) and providing CY24 revenue guidance of US$74-76 For personal use only million (27-30% pcp growth).1 Product shipments to TELA Bio continue to re-alig
Slide 8: Clinical Evidence
|8 Clinical Evidence Enrolments completed for two clinical studies; the pilot study assessing Enivo , AROA’s new tissue apposition platform technology, and the Myriad Augmented Soft Tissue Regeneration Registry For personal use only (‘MASTRR’) AROA expects to commence publishing study results from Q
Slide 9: Q&A
? For personal use only Q&A Unlocking regenerative healing for everybody
Slide 10: Contact
CONTACT For personal use only James Agnew m +64 21 744 915 investor@aroa.com Visit our website www.aroa.com and find us on LinkedIn at www.linkedin.com/company/aroa-biosurgery-limited/ 64 Richard Pearse Drive, PO Box 107111, Auckland Airport, Auckland 2150, Auckland 2022, New Zealand New Zealand Unl